TAF1 and head and neck squamous cell carcinoma: Besides, we found that HNSCC patients at high risk may benefit from a variety of antineoplastic agents, such as AZD6482, TAF1, Ribociclib, LGK974, PF4708671 and others, it provides different therapeutic recommendations for individuals with different risks.